Afuco™ Anti-Human IL22RA ADCC Therapeutic Antibody (ARGX-112), ADCC Enhanced
Anti-IL22RA ADCC Enhanced Antibody (ARGX-112) is an ADCC enhanced antibody produced by our Afuco™ platform. ARGX-112 is a novel, fully human antibody neutralizing both IL20 and IL22 signaling through blockade of their common receptor, IL22R, with low picomolar potency. IL20 and IL22 are involved in proliferation and differentiation of keratinocytes (skin cells) and when over-expressed, are implicated in autoimmune diseases of the skin, including atopic dermatitis, psoriasis and pustular psoriasis. ARGX-112 has been shown to be highly effective in several preclinical models of chronic skin inflammation.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-401CL |
| Pricing | Inquiry |
| Host | Human |
| Target | IL22RA |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage. |